References
- Barlam T, Neu H C. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984; 25: 529–531
- Kato N, Watanabe K, Ueno K, Takeda A, Ban Y, Kawada Y. In vitro activity of RU 28965, a new macrolide, against Chlamydia trachomatis and Ureaplasma urealyticum. Chemother 1988; 36(S-4)76–78
- Hara K, Suyama N, Yamaguchi K, Kohno S, Saito A. Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella. J Antimicrob Chemother 1987; 20: 75–80
- Dournon E, Pangon B, Bizet C, Bure A. In vitro activity of roxithromycin compared with that of three other macrolides against Legionella. Br J Clin Pract 1988; 42(Suppl 55)17–18
- Tremblay D, Bryskier A, Vuckovic M, Stockis A, Manuel C. RU 28965, noveau macrolide semi-synthethique. Biodisponibilité et profil pharmacocinetique apres administration par voie orale. Pathol Biol 1985; 33: 502–506
- Puri S K, Lassman H B. Roxithromycin: A pharmacokinetic review of a macrolide. J Antimicrob Chemother 1987; 20: 89–100
- Birkett D J, Robson D J, Grurinovich N, Tonin A. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther Drug Monit 1990; 12: 65–71
- Herron J M. Roxithromycin in the therapy of Streptococcus pyogenes throat infections. J Antimicrob Chemother 1987; 20: 139–144
- Gentry L O. Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: An overview. J Antimicrob Chemother 1987; 20: 145–152
- Gerson M. Choix d'un macrolide: Les interactions peuvent faire la différence. La Rev Prescrire 1989; 9: 112–114
- Bergogne-Berezin E. Tissue distribution of roxithromycin. J Antimicrob Chemother 1987; 20: 113–120
- Fernandes MacLoughlin G J, Lanoel J L, Stamboulian D, Sarachian B. Roxithromycin in the treatment of atypical pneumonia. Br J Clin Pract 1988; 42(Suppl. 55)92–93
- Grassi C, Bartucci F, Sassella D. Efficacy and safety of roxithromycin in respiratory tract infections. Br J Clin Pract 1988; 42(Suppl. 55)104–106
- Peterslund N A, Hänninen P, Schreiner A, Black F T, Hulten V. Roxithromycin in the treatment of pneumonia. J Antimicrob Chemother 1989; 23: 737–741
- Bertrand A, Caubarrere I, Chapman A, Clavier J, Constans P, Delaval P, Dellamonica P, Deville J F, Remy G, Fressinaud P, Godard P, Grosbuis S, Lacut J Y, Lavandier M, Lemercier J P, Leng J J, Leophonte P, Liozon F, Letellier P, Morere P. Multicentre comparative study of the efficacy and safety of roxithromycin and erythromycin ethyl succinate in the treatment of lower respiratory tract infections. Br J Clin Pract 1988; 42(Suppl. 55)98–99
- Hubrechts J M, Kupperberg A, Smets P, Dramaix M, Valante F, Vanhoof R. Multicentre comparative study of oral roxithromycin and amoxycillin in the treatment of respiratory tract infections. Br J Clin Pract 1988; 42(Suppl. 55)102–103
- Zeluff B J, Lowe P, Koornhof H J, Gentry L O. Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 1988; 7: 69–71
- Charpin J, Freour P, Marsac J. Etude multicentrique de I'efficacité clinique et de la tolérance de la roxithromycin comparée á la doxycycline dans les infections respiratoires basses. Pathologie 1988; 36: 548–551
- Saint-Salvi B, Tremblay D, Surjus A, Lefebvre M A. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother 1987; 20: 121–129
- Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 1984; 247: G688–G694
- Lothe L. Studies on infantile colic with special reference to cows milk whey protein, macro-molecular absorption and regulatory peptides. Thesis, University of Lund, Sweden 1989
- Itoh Z, Omura S. Effect of roxithromycin on gastrointestinal contractile activity: analysis of side effects on the digestive tract. Br J Clin Pract 1988; 42(Suppl. 55)70–72